EAST LYME, Conn. Phesi, a data-driven provider of premier integrated clinical development analytics products and services, today announced that OncoSec Medical Incorporated (OncoSec) (NASDAQ:ONCS) has purchased a multi-year ClinSite™ license to enable more accurate and precise planning for Phase 2 and 3 clinical trials of anticancer immunotherapies developed with OncoSec’s plasmid DNA delivery platform. ClinSite is a self-service, artificial intelligence (AI)-powered…
EAST LYME, Conn. Phesi is delighted to announce the appointment of Dan Manak to the role of Executive Director for Business Development. Dan is based in the US and has been working in pharma and clinical research for over 20 years, selling advanced clinical data analytics and AI technology and services to sponsor companies, enabling site selection and site management. On…
Journalist Dick Anderson conducted an interview with Dr. Gen Li, founder and president of Phesi. Gen Li was an instructor of neuroscience at Weill Cornell Medicine in 1996 when he enrolled in the inaugural class of Johnson’s One-Year MBA program for students with advanced technology degrees. He recalls a team-building session when a peer said, “Gen, you have an amazing capability in seeing…
(CROWN CONGRESS) January 22 2019 Phesi is a proud sponsor and presenter at the 8th CROWN congress in Orlando, Florida. The CMO of Phesi, Dr. Paul Chew gives a talk titled “Smarter Trials = Faster Cures: 3 Things You Need to Get Right”. The presentation slides can be downloaded here. About the 8th CROWN congress This year’s CROWN Congress will…
(BUSINESS WIRE) October 10, 2018 EAST LYME, Conn. Phesi, a technology-enabled, data-driven provider of premier clinical development services, today announced it is a finalist for a 2018 Scrip Award, one of the pharmaceutical and biotech industries’ most prestigious honors. The company has been selected as one of six finalists in the Best Technological Development in Clinical Trials – Tech Sponsor-focused…